JDRF Awards $9 Million US for Phase 3 Type 1 Diabetes Kidney Disease Clinical Trial, Joins The Kidney Foundation of Canada in Driving Research to Treat Kidney Disease
Retrieved on:
Monday, January 22, 2024
Diabetes, Patient, Research, Diabetic nephropathy, Kidney, Kidney failure, Person, T1D, CIHR, SGLT2, Team, University, Kidney disease, Joslin Diabetes Center, Risk, KFOC, Type 2 diabetes, Safety, Public, University of Toronto, SGLT, JDRF, Clinical trial, University Health Network, Pharmaceutical industry
Kidney disease remains a life-threatening complication for those living with diabetes.
Key Points:
- Kidney disease remains a life-threatening complication for those living with diabetes.
- Almost half of kidney failure cases are caused by diabetes, and an estimated one out of three people with T1D develop significant kidney disease.
- SUGARNSALT is one of the largest T1D focused kidney disease studies in the world, and it is the only phase 3 clinical trial targeting major kidney disease outcomes.
- "The Kidney Foundation of Canada is proud to be one of the founding partners on this significant investment to support innovative strategies to treat diabetic kidney disease.